

Licensing Opportunity (BioT-1369/1329-UMG) **Antibody Therapy and Diagnosis of Alzheimer's Disease**

Alzheimer's Disease (AD) is the main neurodegenerative disease worldwide affecting more than 29 Mill. people. By 2050 the prevalence will quadruple, by thich time 1 in 85 persons worldwide will be living with AD. AD still features high growth potential and room for further innovation due to the huge worldwide growth of the number of patients and the lack of efficacious drugs.

Scientists at the University of Göttingen developed a novel proprietary Antibody for the Therapy and/or Diagnosis of Alzheimer's Disease (AD).

Hallmarks


- New proprietary Antibody against Alzheimer's Disease (9D5 mouse anti human).
- Antibody selectively targets pyro-Glu-Abeta peptide oligomers.
- Oligomeric pyro-Glu-Abeta peptides are the triggers of Abeta aggregation and plaque formation, thus of AD.
- Intraneuronal pyro-Glu-Abeta 3-42 peptide is toxic and triggers neurodegeneration and lethal neurological deficits.
- To be used for sporadic AD and most familiar AD forms.
- Blood ELISA test for diagnosis achieved.
- *In vivo* proof of concept successfully achieved.

Uses (1) Diagnosis

- ★ Blood sample.
- ★ ELISA quick and easy measurement.
- ★ Companion therapeutical efficacy test.


(2) Therapeutic

- ★ AD therapy based on proprietary antibody.




THERAPEUTIC Proof of Concept


(1) Therapeutical effect: Rescue of behavioral deficits



Cross-maze



Elevated plus maze




ELISA assay

In vivo tests after passive immunisation with our proprietary **9D5 antibody** for six weeks in AD mice model (age at analysis six months). Black = 9D5 injection, gray = PBS injection.


(2) Reduction of plaque load:

Reduction of total Abeta, Abeta3pGlu, Abeta-40 and Abeta-42 plaque load



AD Diagnosis

ELISA with proprietary antibody shows reduced human plasma levels of pyro-Glu-Abeta peptide oligomers in patient samples.



References: J. Biol. Chem. jbc.M110.178707 ePub ahead of print.

We filed a portfolio of patent applications and are now **looking for companies, which are interested in licensing, developing and commercializing our approach.**